← Back to Search

Telemonitoring for Heart Failure

N/A
Recruiting
Led By Martin Cadeiras, MD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of Heart failure
Objective evidence of cardiac abnormality of structure or function (abnormal ECHO) or elevated levels of B-type natriuretic peptide (>100 pg/ml)
Must not have
Patients unable to consent
History of HTx
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year from enrollment
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether using data from different 'omics' studies can help identify people at risk for heart failure, and whether a telemonitoring intervention can help optimize their care.

Who is the study for?
This trial is for individuals with heart failure who have evidence of cardiac issues or high levels of a specific heart stress marker. They must be in any stage or class of heart failure, able to consent, follow the study's protocol, use a smartphone regularly, and not have had a heart transplant or mechanical circulatory support.
What is being tested?
The study is exploring if advanced testing can predict which patients with heart failure are at higher risk and whether monitoring these patients using telemonitoring devices can help optimize their treatment according to established guidelines.
What are the potential side effects?
Since this trial involves telemonitoring devices rather than medication, side effects may include discomfort from wearing the device and potential privacy concerns related to data transmission. There might also be psychological impacts due to constant health monitoring.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with heart failure.
Select...
I have heart issues shown by tests or high BNP levels.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am unable to give consent by myself.
Select...
I have had a heart transplant.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~five years from enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and five years from enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of adverse outcomes in heart failure
Secondary study objectives
Disease progression
Other study objectives
Percentage of guideline-directed medical therapy (GDMT).

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TelemonitoringExperimental Treatment1 Intervention
Blood pressure and heart rate monitoring, scale, activity tracker.
Group II: No interventionActive Control1 Intervention
No intervention.

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
942 Previous Clinical Trials
4,755,575 Total Patients Enrolled
6 Trials studying Heart Failure
2,490 Patients Enrolled for Heart Failure
Martin Cadeiras, MDPrincipal InvestigatorUniversity of California, Davis
1 Previous Clinical Trials
9 Total Patients Enrolled

Media Library

Telemonitoring devices Clinical Trial Eligibility Overview. Trial Name: NCT04196842 — N/A
Heart Failure Research Study Groups: No intervention, Telemonitoring
Heart Failure Clinical Trial 2023: Telemonitoring devices Highlights & Side Effects. Trial Name: NCT04196842 — N/A
Telemonitoring devices 2023 Treatment Timeline for Medical Study. Trial Name: NCT04196842 — N/A
~19 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top